carbonthatcarbonthat
← Every company

Pacira Biosciences Inc Insider Trading

Every director, officer and 10% holder of Pacira Biosciences Inc has to report each trade in its stock within two business days of making it. This is those filings.

PCRX on carbonthat →
Insiders filing
2
4 reported lines
Open-market buys
0
Open-market sales
2
$288.5K
Net
$288.5K
sold more

Purchases and sales

Open-market trades only — the lines where someone chose to buy or sell at the going price.

InsiderActionValue
Lauren RikerSenior Vice President, Finance2026-10-086K shat $36.32
Sale10b5-1 plan
$217.9K
Jonathan SloninChief Medical Officer2026-08-173K shat $23.23
Sale10b5-1 plan
$70.6K

Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.

More on PCRX

Company overviewEverything on PCRX in one place, with the price.SEC filingsWhat PCRX's 8-Ks say happened: results, departures, auditor changes.Planned salesSales PCRX insiders have filed notice of.Who owns itEvery manager reporting a position in PCRX.Funds holding itWhich funds and ETFs hold PCRX, and how big a bet.

Follow Pacira Biosciences Inc (PCRX) by email

New trades in Pacira Biosciences Inc (PCRX) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.

Unsubscribe with one click from any email.

Related datasets

PeopleCEOs, investors, public officials and market commentators.SEC FilingsAuditor changes, restatements, departures and results, from 8-Ks.Insider BuyingCluster buys, and chief executives buying their own stock.The InsidersOne page per filer: every company they file against.